CDC|ACIP Influenza Vaccine Advice for the 2018-19 Influenza Season

In September, the ACIP issued guidance updating their 2017 to 2018 recommendations regarding the use of seasonal influenza vaccines and advises vaccine providers regarding the use of influenza vaccines for influenza prevention and control during the 2018 to 2019 season. 

Key CDC ACIP Messages Regarding the 2018-19 Flu Vaccine

  • Specific recommendations address the vaccine virus composition for 2018 to 2019 US seasonal influenza vaccines, use of LAIV4 for persons in whom it is appropriate, influenza vaccination of persons with a history of egg allergy, and recent regulatory actions, including new vaccine licensures and labeling changes.

  • Updated ACIP recommendations for the 2018 to 2019 influenza season include vaccine virus composition for 2018 to 2019 US seasonal influenza vaccines and a recommendation that LAIV4 is an option for influenza vaccination of persons for whom it is appropriate.
  • Updated ACIP recommendations for the 2018 to 2019 influenza season note that persons with a history of egg allergy may receive any licensed, recommended, and age-appropriate influenza vaccine (IIV, RIV4, or LAIV4) and describe new vaccine licensures and labeling changes for previously licensed vaccines.
  • Implications for the Healthcare Team: ACIP recommends routine annual influenza vaccination for all persons without contraindications aged at least 6 months, using a licensed, recommended, and age-appropriate vaccine. Members of the healthcare team need to remain current regarding vaccine recommendations and work together to promote prevention and control of seasonal influenza.

To read the ACIP recommendations on the CDC website- click here.